Oxford BioTherapeutics
PrivateLast Round
VC Round
Feb 1, 2020
Total Funding Raised
$20M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Oxford BioTherapeutics operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a VC Round in February 2020.
Oxford BioTherapeutics is a clinical-stage oncology company that develops first-in-class antibody-based therapies, including antibody-drug conjugates (ADCs) and immuno-oncology (IO) treatments, using its proprietary OGAP® proteomic target discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oxford BioTherapeutics Comparables
Compare Oxford BioTherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MBrace Therapeutics | 77% | |
| ProFound Therapeutics | 77% | |
| Ona Therapeutics | 76% |
For institutional investors. Book with your work email.
Oxford BioTherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Feb 1, 2020 | ||||
| VC Round | Mar 14, 2019 | ||||
| Debt | Jan 26, 2017 | ||||
| Debt | Jul 30, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Oxford BioTherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Calculus Capital | VC Round |
| Oxford Capital | VC Round |
| Oxford Finance | Debt |
| Catapult Ventures | VC Round |
| Silicon Valley Bank | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 10, 2026
Open roles increased to 37, representing 52% of headcount.
- Jul 27, 2026
Open roles increased to 35, representing 49% of headcount.
For institutional investors. Book with your work email.
Oxford BioTherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Oxford BioTherapeutics's valuation, stock price, and market status.
Is Oxford BioTherapeutics a public or private company?
Oxford BioTherapeutics is a private company.
What is the current stock price of Oxford BioTherapeutics?
Oxford BioTherapeutics is a private company, so its shares have no public market price. Caplight tracks Oxford BioTherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oxford BioTherapeutics worth (valuation)?
Valuation information for Oxford BioTherapeutics is not publicly available.
Can I buy Oxford BioTherapeutics stock?
Oxford BioTherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oxford BioTherapeutics's last funding round?
Oxford BioTherapeutics's most recent funding round was VC Round on February 1, 2020.
Who are the main investors in Oxford BioTherapeutics?
Key investors in Oxford BioTherapeutics include Oxford Finance, Silicon Valley Bank.
Will Oxford BioTherapeutics IPO soon?
No public IPO plans have been announced for Oxford BioTherapeutics.
How can I track Oxford BioTherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Oxford BioTherapeutics's shares on secondary markets.